ZTS Stock Summary and Trading Ideas (Zoetis Class A | NYSE:ZTS)

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis Class A trades on the NYSE stock market under the symbol ZTS.

As of February 13, 2025, ZTS stock price declined to $164.93 with 11,712,668 million shares trading.

ZTS has a beta of 0.46, meaning it tends to be less sensitive to market movements. ZTS has a correlation of 0.06 to the broad based SPY ETF.

ZTS has a market cap of $74.41 billion. This is considered a Large Cap stock.

Last quarter Zoetis Class A reported $2 billion in Revenue and $1.58 earnings per share. This beat revenue expectation by $98 million and exceeded earnings estimates by $.13.

In the last 3 years, ZTS traded as high as $201.92 and as low as $124.15.

The top ETF exchange traded funds that ZTS belongs to (by Net Assets): VTI, VOO, SPY, IVV, VUG.

ZTS has underperformed the market in the last year with a price return of -15.2% while the SPY ETF gained +23.1%. ZTS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.9% and -3.1%, respectively, while the SPY returned +2.5% and +1.3%, respectively.

ZTS support price is $171.33 and resistance is $176.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZTS shares will trade within this expected range on the day.